Evidence map›Paper›PMID 37085489›Full record

ArticleNature communications2023

Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6.

Taha Y Taha, Irene P Chen, Jennifer M Hayashi, Takako Tabata, Keith Walcott, Gabriella R Kimmerly, Abdullah M Syed, Alison Ciling, Rahul K Suryawanshi, Hannah S Martin and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A bireporter recombinant SARS-CoV-2 Omicron BA.5 forbioRxiv : the preprint server for biology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.bioRxiv : the preprint server for biology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Taha Y Taha *Gladstone Institutes, San Francisco, CA, USA. taha.taha@gladstone.ucsf.edu.ORCID 0000-0002-7344-7490
Irene P Chen *Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-5766-9253
Jennifer M Hayashi *Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0001-7153-9212
Takako Tabata *Gladstone Institutes, San Francisco, CA, USA.
Keith WalcottGladstone Institutes, San Francisco, CA, USA.ORCID 0000-0003-2896-2431
Gabriella R KimmerlyGladstone Institutes, San Francisco, CA, USA.
Abdullah M SyedGladstone Institutes, San Francisco, CA, USA.
Alison CilingGladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-8393-6829
Rahul K SuryawanshiGladstone Institutes, San Francisco, CA, USA.
Hannah S MartinGladstone Institutes, San Francisco, CA, USA.
Bryan H BachInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID 0000-0003-1420-6344
Chia-Lin TsouGladstone Institutes, San Francisco, CA, USA.
Mauricio MontanoGladstone Institutes, San Francisco, CA, USA.
Mir M KhalidGladstone Institutes, San Francisco, CA, USA.
Bharath K SreekumarGladstone Institutes, San Francisco, CA, USA.
G Renuka KumarGladstone Institutes, San Francisco, CA, USA.
Stacia WymanInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID 0000-0002-8937-8397
Jennifer A DoudnaGladstone Institutes, San Francisco, CA, USA.ORCID 0000-0001-9161-999X
Melanie OttGladstone Institutes, San Francisco, CA, USA. melanie.ott@gladstone.ucsf.edu.ORCID 0000-0002-5697-1274

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4M
Suppression of Host Antiviral Responses by a SARS-CoV-2 Histone MimeticF31AI164671 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, IRENE PO-RU · 2021 to 2022
$82k
NIAID NIH HHS F31 AI164671NIAID NIH HHS U19 AI171110
6 · The paper itself

Abstract

Although the SARS-CoV-2 Omicron variant (BA.1) spread rapidly across the world and effectively evaded immune responses, its viral fitness in cell and animal models was reduced. The precise nature of this attenuation remains unknown as generating replication-competent viral genomes is challenging because of the length of the viral genome (~30 kb). Here, we present a plasmid-based viral genome assembly and rescue strategy (pGLUE) that constructs complete infectious viruses or noninfectious subgenomic replicons in a single ligation reaction with >80% efficiency. Fully sequenced replicons and infectious viral stocks can be generated in 1 and 3 weeks, respectively. By testing a series of naturally occurring viruses as well as Delta-Omicron chimeric replicons, we show that Omicron nonstructural protein 6 harbors critical attenuating mutations, which dampen viral RNA replication and reduce lipid droplet consumption. Thus, pGLUE overcomes remaining barriers to broadly study SARS-CoV-2 replication and reveals deficits in nonstructural protein function underlying Omicron attenuation.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19SARS-CoV-2AnimalsGenome, ViralRNA, ViralSubgenomic RNAViral Nonstructural ProteinsCoronavirus Nucleocapsid ProteinsORF1ab polyprotein, SARS-CoV-2RNA, ViralSubgenomic RNAViral Nonstructural Proteins

Identifiers

PMID37085489
PMCPMC10120482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.